Progesterone receptors in lung cancer progesterone

Progesterone receptors in lung cancer progesterone
mediates cell differentiation through the pr. presence
of pr in breast cancer is, in general, an indication of a more
differentiated tumor that's responsive to antiestrogen therapy,
and pr could be a known estrogen-responsive gene. there are several
reports of expression of pr by primary nsclc, although
there's an excellent deal of variability within the reported frequency of
expression. 114, 115 one report found no pr in nsclc. 116 a
recent report used a monoclonal antibody that recognizes both
the a and b forms of pr and located positive pr expression in
46% of cases, with a preponderance of positive pr expression
in tumors from ladies. 117 enzymes capable of synthesizing
progesterone were conjointly detected in several nsclc, and a positive
correlation was observed between intratumoral levels of
progesterone and also the presence of 3 enzymes that participate
in progesterone synthesis. exposure of nsclcs to progesterone
led to growth inhibition of tumor xenografts and
concomitant induction of apoptosis, in a verygreement with clinical
knowledge, suggesting that the presence of pr was correlated with
longer overall survival in nsclc patients.
progesterone derivatives are useful within the treatment
of each endometrial cancer and breast cancer. 118, 119 agents
like medroxyprogesterone acetate, that may be given orally,
have a possible role within the treatment of lung cancer, maybe in
combination with agents that suppress either the er pathway
or act on growth issue pathways like egfr, mesenchymal–
epithelial transition issue ( c-met ), or different tkis. long-term
progesterone treatment would possibly even be feasible for chemoprevention
of lung cancer.